ROHTO PHARMACEUTICAL CO.,LTD.JP:4527

Market cap
¥706.6B
P/E ratio
41.2
Mar 31,
2013
Mar 31,
2014
Mar 31,
2015
Mar 31,
2016
Mar 31,
2017
Mar 31,
2018
Mar 31,
2019
Mar 31,
2020
Mar 31,
2021
Mar 31,
2022
Mar 31,
2023
Profit (loss) before income taxes13,63014,59913,75114,30314,75216,82016,30021,73023,00627,95334,290
Depreciation
Impairment losses
Amortization of goodwill
Increase (decrease) in allowance for doubtful accounts
Increase (decrease) in provision for bonuses
Increase (decrease) in retirement benefit liability
Bad debt expense-OpeCF
Loss on retirement of non-current assets
Loss on tax purpose reduction entry of non-current assets
National subsidies-OpeCF
Gain on bargain purchase
Loss (gain) on sale of investment securities
Loss (gain) on valuation of investment securities
Loss on valuation of shares of subsidiaries and associates
Interest and dividend income
Interest expenses
Share of loss (profit) of entities accounted for using equity method
Loss (gain) on change in equity
Decrease (increase) in trade receivables
Decrease (increase) in inventories
Increase (decrease) in trade payables
Other, net
Subtotal
Interest and dividends received
Interest paid
Payments for guarantee obligations
Income taxes paid
Income taxes refund
Net cash provided by (used in) operating activities
Payments into time deposits
Proceeds from withdrawal of time deposits
Purchase of property, plant and equipment
Proceeds from sale of property, plant and equipment
Payments for asset retirement obligations
Purchase of intangible assets
Purchase of investment securities
Proceeds from sale and redemption of investment securities
Purchase of shares of subsidiaries resulting in change in scope of consolidation
Subsidies received
Long-term loan advances
Proceeds from collection of long-term loans receivable
Other, net
Net cash provided by (used in) investing activities
Net increase (decrease) in short-term borrowings
Proceeds from long-term borrowings
Repayments of long-term borrowings
Dividends paid
Dividends paid to non-controlling interests
Purchase of shares of subsidiaries not resulting in change in scope of consolidation
Other, net
Net cash provided by (used in) financing activities
Effect of exchange rate change on cash and cash equivalents
Net increase (decrease) in cash and cash equivalents